Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146029
Status:
TERMINATED
Last Update Posted:
2008-03-26
First Post:
2005-09-01
Brief Title:
Companion Pharmacogenetic Study to UMCC 99009901
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme CYP3A4 is present in tumor material The researchers want to see if this is in any way associated with how the patient responded to docetaxel They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes to see if they are normal or if they have polymorphisms or change compared to normal CYP metabolizing enzymes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None